| Intermediate and longer-term outcomes from a prospective active-surveillance program for favorable-risk prostate cancer JJ Tosoian, M Mamawala, JI Epstein, P Landis, S Wolf, BJ Trock, ... Journal of Clinical Oncology 33 (30), 3379-3385, 2015 | 636 | 2015 |
| Germline mutations in ATM and BRCA1/2 are associated with grade reclassification in men on active surveillance for prostate cancer HB Carter, B Helfand, M Mamawala, Y Wu, P Landis, H Yu, K Wiley, R Na, ... European urology 75 (5), 743-749, 2019 | 212 | 2019 |
| Active surveillance of grade group 1 prostate cancer: long-term outcomes from a large prospective cohort JJ Tosoian, M Mamawala, JI Epstein, P Landis, KJ Macura, ... European urology 77 (6), 675-682, 2020 | 206 | 2020 |
| Prostate Health Index density improves detection of clinically significant prostate cancer JJ Tosoian, SC Druskin, D Andreas, P Mullane, M Chappidi, S Joo, ... BJU international 120 (6), 793-798, 2017 | 107 | 2017 |
| The role of multiparametric magnetic resonance imaging/ultrasound fusion biopsy in active surveillance TM Ma, JJ Tosoian, EM Schaeffer, P Landis, S Wolf, KJ Macura, JI Epstein, ... European urology 71 (2), 174-180, 2017 | 95 | 2017 |
| A comprehensive evaluation of CHEK2 germline mutations in men with prostate cancer Y Wu, H Yu, SL Zheng, R Na, M Mamawala, T Landis, K Wiley, ... The Prostate 78 (8), 607-615, 2018 | 81 | 2018 |
| Estimation of COVID-19 mRNA vaccine effectiveness and COVID-19 illness and severity by vaccination status during Omicron BA. 4 and BA. 5 sublineage periods R Link-Gelles, ME Levy, K Natarajan, SE Reese, AL Naleway, SJ Grannis, ... JAMA network open 6 (3), e232598-e232598, 2023 | 70 | 2023 |
| Effectiveness of COVID-19 mRNA vaccines against COVID-19–associated hospitalizations among immunocompromised adults during SARS-CoV-2 Omicron predominance—VISION Network, 10 … A Britton MMWR. Morbidity and Mortality Weekly Report 71, 2022 | 69 | 2022 |
| Effectiveness of homologous and heterologous COVID-19 booster doses following 1 Ad. 26. COV2. S (Janssen [Johnson & Johnson]) vaccine dose against COVID-19–associated emergency … K Natarajan MMWR. Morbidity and Mortality Weekly Report 71, 2022 | 58 | 2022 |
| Evaluating the impact of length of time from diagnosis to surgery in patients with unfavourable intermediate‐risk to very‐high‐risk clinically localised prostate cancer N Gupta, TJ Bivalacqua, M Han, MA Gorin, BJ Challacombe, AW Partin, ... BJU international 124 (2), 268-274, 2019 | 57 | 2019 |
| Pathologic outcomes in favorable-risk prostate cancer: comparative analysis of men electing active surveillance and immediate surgery JJ Tosoian, D Sundi, BJ Trock, P Landis, JI Epstein, EM Schaeffer, ... European urology 69 (4), 576-581, 2016 | 53 | 2016 |
| Longitudinal assessment of urinary PCA3 for predicting prostate cancer grade reclassification in favorable-risk men during active surveillance JJ Tosoian, HD Patel, M Mamawala, P Landis, S Wolf, DJ Elliott, ... Prostate cancer and prostatic diseases 20 (3), 339-342, 2017 | 47 | 2017 |
| Transperineal prostate biopsy improves the detection of clinically significant prostate cancer among men on active surveillance AR Meyer, M Mamawala, JS Winoker, P Landis, JI Epstein, KJ Macura, ... The Journal of urology 205 (4), 1069-1074, 2021 | 44 | 2021 |
| Risk prediction tool for grade re‐classification in men with favourable‐risk prostate cancer on active surveillance MM Mamawala, K Rao, P Landis, JI Epstein, BJ Trock, JJ Tosoian, ... BJU international 120 (1), 25-31, 2017 | 41 | 2017 |
| Conditional probability of reclassification in an active surveillance program for prostate cancer R Alam, HB Carter, P Landis, JI Epstein, M Mamawala The Journal of urology 193 (6), 1950-1955, 2015 | 37 | 2015 |
| A Bayesian hierarchical model for prediction of latent health states from multiple data sources with application to active surveillance of prostate cancer RY Coley, AJ Fisher, M Mamawala, HB Carter, KJ Pienta, SL Zeger Biometrics 73 (2), 625-634, 2017 | 35 | 2017 |
| Genetic factors associated with prostate cancer conversion from active surveillance to treatment Y Jiang, TJ Meyers, AA Emeka, LF Cooley, PR Cooper, N Lancki, ... Human Genetics and Genomics Advances 3 (1), 2022 | 31 | 2022 |
| Prostate Health Index and multiparametric magnetic resonance imaging to predict prostate cancer grade reclassification in active surveillance ZR Schwen, M Mamawala, JJ Tosoian, SC Druskin, AE Ross, LJ Sokoll, ... BJU international 126 (3), 373-378, 2020 | 31 | 2020 |
| Utility of multiparametric magnetic resonance imaging in the risk stratification of men with Grade Group 1 prostate cancer on active surveillance MK Mamawala, AR Meyer, PK Landis, KJ Macura, JI Epstein, AW Partin, ... BJU international 125 (6), 861-866, 2020 | 29 | 2020 |
| Prediction of the pathologic Gleason score to inform a personalized management program for prostate cancer RY Coley, SL Zeger, M Mamawala, KJ Pienta, HB Carter European urology 72 (1), 135-141, 2017 | 28 | 2017 |